Abstract:A prospective phase II trial was conducted to investigate the diagnosis of leptomeningeal metastases (LMs) and clinical outcomes of comprehensive treatment. Patients who were clinically suspected to have LMs and received comprehensive treatment based on tomotherapy were enrolled. Whole brain radiotherapy (WBRT) with or without simultaneously boost to LM or craniospinal irradiation (CSI) was given to them. The diagnosis and response were assessed by the results of enhanced MRI, clinical signs and symptoms, cerebrospinal fluid (CSF) cytology and liquid biopsy and liquid genomics detection. The primary endpoint was local control (LC), and the secondary endpoints were intracranial progression-free survival (IPFS) and overall survival (OS). Kaplan-Meier method was used. From 2014 to 2017, 88 patients were enrolled (Male: Female=36:52), and the median age was 55 years old (range, 29-81). The major primary diagnosis was non-small cell lung cancer (64.8%). Typical clinical signs included cerebral (70.5%), cranial nerve palsies (30.7%), and spinal complaints (33.0%). 20.5% of patients showed no obvious symptoms. MRI findings before treatment included 4 types: multiple brain metastases (BMs) with focal LMs, large BMs invaded meningeal, extensive LMs and LMs proved by clinical symptoms or CSF without changes in MRI. The lesions appeared as nodular (67.1%), linear enhancement (18.2%), both (10.2%), or narrowing brain fold without other appearance (4.5%). MRI changes after radiation mainly included decreased lesions and weakened enhancement (65.9%), increased and strengthened followed by decreased lesions and weakened enhancement (18.2%), and increased lesions and strengthened enhancement but with cystic change (5.7%). 9 patients were diagnosed with distinct spinal cord metastases. 31 patients received lumbar puncture, and CSF cytology mainly showed increased leukocyte counts (64.5%), evaluated protein (54.8%) and decreased glucose (51.6%). 19 patients found tumor cells and were administrated intrathecal chemotherapy (mostly methotrexate; the median cycles were 4), in which 9 turned to be negative. 4 patients received CSF genetic testing and 2 were detected mutation. 60 patients used target therapy. Patients received WBRT with boost (40 Gy in 20 fractions (f) for WBRT and 60Gy in 20 f for boost; 64.8%), focal radiation to LMs (26.2%), WBRT and CSI (50 Gy in 25 f for WBRT and 36 Gy in 20 f for CSI; 9.1%). Response rates of CR, PR, and SD were 5.7%, 71.6%, and SD 13.6%, respectively. The median follow-up and survival time was 13.5 and 17.6 months, respectively. The 1-year LC, IPFS, and OS were 75.2%, 52.9%, and 71.3%, respectively. Neuroimaging, clinical signs and CSF findings may be prior inspection items for diagnosis of LMs. Early detection with reasonable comprehensive treatment including precise radiotherapy, intrathecal chemotherapy and targeted agents can improve local control and survival time of these patients.

Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care

Leptomeningeal metastatic disease: new frontiers and future directions

A Preclinical Model of Patient-Derived Cerebrospinal Fluid Circulating Tumor Cells for Experimental Therapeutics in Leptomeningeal Disease from Melanoma.

Breast leptomeningeal disease: a review of current practices and updates on management

Leptomeningeal Disease and the Evolving Role of Molecular Targeted Therapy and Immunotherapy

The Diagnosis and Comprehensive Treatment of Leptomeningeal Metastasis: A Phase II Trial

LMD-03. Single Cell Analysis Reveals How Therapy Remodels the Tumor Microenvironment in Melanoma CNS Metastases and Uncovers a Novel Predictor of Improved Survival

P05.24 the Diagnosis and Comprehensive Treatment of Leptomeningeal Metastases--results of a Phase II Trial

Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.

Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions

Treatment Advances in Lung Cancer with Leptomeningeal Metastasis

Intrathecal Anti-Pd-1 Treatment in Patients with Metastatic Melanoma (MM) with Leptomeningeal Disease (LMD): Real-world Data and Evidence

Intrathecal anti-PD-1 treatment in metastatic melanoma patients with leptomeningeal disease (LMD): real-world data and evidence

Overview of recent trends in diagnosis and management of leptomeningeal multiple myeloma

Case Report: Concurrent Intrathecal and Intravenous Pembrolizumab for Metastatic Melanoma with Leptomeningeal Disease

Research Advances in Leptomeningeal Metastasis from Non-small Cell Lung Cancer

Leptomeningeal metastasis from systemic cancer: Review and update on management

Top Ten Tips Palliative Care Clinicians Should Know About Caring for People with Leptomeningeal Disease

Drug delivery in leptomeningeal disease: Navigating barriers and beyond

Treatment And Prognostic Analysis Of Patients With Leptomeningeal Metastases From Non-Small Cell Lung Cancer

A comprehensive review of current treatment modalities for leptomeningeal carcinomatosis in breast cancer